Achieve Life Sciences Announces Publication Of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial In Journal Of The American Medical Association
Portfolio Pulse from Benzinga Newsdesk
Achieve Life Sciences has announced the publication of its Phase 3 ORCA-2 Smoking Cessation Trial in the Journal of the American Medical Association. The trial demonstrated the efficacy and tolerability of cytisinicline, a potential pharmacotherapy for smoking cessation. This could be the first such therapy approved in nearly two decades.
July 11, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
While SCHV is mentioned in the article, it does not appear to be directly impacted by the news of Achieve Life Sciences' Phase 3 ORCA-2 Smoking Cessation Trial results.
SCHV is mentioned in the article, but there is no clear link between the ETF and the news about Achieve Life Sciences' Phase 3 ORCA-2 Smoking Cessation Trial results. Therefore, it is unlikely that this news will have a significant impact on SCHV's price.
CONFIDENCE 90
IMPORTANCE 10
RELEVANCE 10
POSITIVE IMPACT
The publication of Achieve Life Sciences' Phase 3 ORCA-2 Smoking Cessation Trial results could potentially boost the company's stock as it shows the efficacy of cytisinicline, a potential smoking cessation therapy.
The publication of positive trial results in a reputable journal like JAMA is a significant milestone for Achieve Life Sciences. It not only validates the efficacy of cytisinicline but also increases the likelihood of it being approved as a smoking cessation therapy. This could potentially lead to increased revenues for the company, thereby boosting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100